Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 1403 of 5804
-
Massive brain chart project aims to spot Alzheimer's and MS earlier
Knowledge-focused ENROLLING_BY_INVITATIONMajor brain diseases (including neuroimmune diseases, neurodegenerative diseases, and cerebrovascular diseases) are leading causes of death and disability in humans. This research will gather brain imaging data from more than 10,000 participants across multiple age groups from mu…
Sponsor: Beijing Tiantan Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:07 UTC
-
Exercise as medicine: HIIT may slow glaucoma damage
Disease control OngoingHIT GLAUCOMA is a multicenter exercise study for glaucoma patients between three institutes: the Department of Sport, Exercise and Health (DSBG) of the University of Basel, the Eye Clinic at the University Hospital Basel and the UZ Leuven (Belgium). The main objective of the stud…
Phase: NA • Sponsor: Henner Hanssen • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
Can we predict who will benefit most from atrial fibrillation ablation?
Knowledge-focused CompletedAtrial fibrillation (AF) is a prevalent cardiac arrhythmia affecting millions globally, with projections indicating a doubling of cases by 2050. AF is linked to heightened cardiovascular risks like stroke and increased healthcare costs. Ablation, targeting the arrhythmia substrat…
Sponsor: Medical University of Warsaw • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:03 UTC
-
New cancer drug BNT314 enters first human safety trial
Disease control OngoingThe purpose of this first-in-human study is to find out if BNT314 is safe when it is used alone in patients with different types of cancer. This is a dose escalation study in which patients will be assigned to multiple dose levels (DLs) of BNT314 given alone. By escalating the d…
Phase: PHASE1 • Sponsor: BioNTech SE • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
Experimental cell therapy aims to boost immune system against Hard-to-Treat prostate cancer
Disease control CompletedThis is an open-label, phase I/IIa dose escalation and expansion study of INKmune in men with mCRPC. INKmune is administered to patients intravenously over three doses, at least one-week apart. The study will consist of two stages.
Phase: PHASE1, PHASE2 • Sponsor: Inmune Bio, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
Could Once-Daily radiation replace Twice-Daily for breast cancer recurrence?
Disease control Recruiting nowThe standard treatment for participants whose cancer has returned after breast conserving surgery is radiation given twice daily (separated by at least 6 hours) for a total of 30 treatments. The purpose of this study is to find out if giving radiation once a day for 15 treatments…
Phase: PHASE2 • Sponsor: Case Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Spinal fluid injection shows promise for tough lung cancer spread
Disease control Recruiting nowThis is a prospective, single-arm, open clinical study, which was designed to evaluate the efficacy and safety of an immune checkpoint inhibitor combined with pemetrexed intrathecal injection in the treatment of patients with NSCLC associated with leptomeningeal metastases.
Phase: PHASE2 • Sponsor: West China Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
New drug MTX325 enters first human tests for Parkinson's
Disease control Recruiting nowThe goal of this trial is to learn if MTX325 can be developed as a potential disease-modifying treatment for Parkinson's Disease. Parts 1-4 complete, Part 5 (multiple doses in patients with Parkinson's Disease) in progress.
Phase: PHASE1 • Sponsor: Mission Therapeutics • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
New hope for older lymphoma patients: gentler drug combo shows promise
Disease control OngoingThis is a phase II, single-arm, open-label, multicentre study of acalabrutinib and rituximab for elderly or frail patients with previously untreated mantle cell lymphoma.
Phase: PHASE2 • Sponsor: University College, London • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
What drives people to Self-Treat with psychedelics? a study investigates
Knowledge-focused CompletedThis study is set up to better understand the current use of psychedelics in France in the general population. The present focus on individuals who have used any type of psychedelic drug in order to suppress or alleviate a psychiatric symptom in the context of a diagnosed patholo…
Sponsor: University Hospital, Toulouse • Aim: Knowledge-focused
Last updated Jul 25, 2026 00:00 UTC
-
New shot could tame stubborn hives when other treatments fail
Disease control OngoingThis trial will be performed as a three-part dose escalating clinical trial where Parts 1 is open label and Parts 2 and 3 are randomized, double-blinded, and placebo-controlled. The trial is intended to determine the safety and tolerability and assess the preliminary efficacy of…
Phase: PHASE1, PHASE2 • Sponsor: Jasper Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
Brain MRI screening for breast cancer: a new way to catch metastases early?
Diagnosis Recruiting nowThe goal of this multi-centre, prospective study is to assess the frequency of asymptomatic brain metastasis in patients with stage IIb or III Triple Negative or HER2 positive breast cancer. The main questions it aims to answer are: 1. What proportion of patients with stage IIb …
Phase: NA • Sponsor: Sunnybrook Health Sciences Centre • Aim: Diagnosis
Last updated Jun 27, 2026 08:05 UTC
-
Can a smartphone app and video therapy help young people with HIV?
Disease control OngoingThe goal of this randomized clinical trial is to test the effect of a technology-based intervention with an Adaptive Treatment Strategy (ATS) among youth living with HIV (YLWH) (18-29 years old). This piloted and protocolized intervention combines: (1) brief weekly sessions with …
Phase: NA • Sponsor: University of California, San Francisco • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
Can a family advocate help break the cycle of trauma and addiction?
Prevention Recruiting nowPrimary Objective: Conduct a rigorous evaluation of a prevention-based intervention designed to mitigate the harms of adverse childhood experiences (ACEs) exposure and prevent future ACEs, substance use, and overdose within 36 communities experiencing a disproportionate burden of…
Phase: NA • Sponsor: RTI International • Aim: Prevention
Last updated Jun 27, 2026 12:28 UTC
-
New nasal spray could offer quick migraine relief for asian patients
Symptom relief CompletedThe purpose of this study is to learn how safe and effective zavegepant is compared to placebo in the acute treatment of migraine in Asian adults. Migraine is a very painful headache with other associated symptoms such as nausea, photophobia and phonophobia. A placebo is a harmle…
Phase: PHASE3 • Sponsor: Pfizer • Aim: Symptom relief
Last updated Jun 27, 2026 12:37 UTC
-
Could a chatty flowerpot robot reduce caregiver dependence?
Disease control CompletedThe goal of this multiple baseline single case study is to study the (cost)effectiveness of a social robot in reducing professional caregiver support and promoting independence for individuals in long-term disability care experiencing problems with daily structure and planning. T…
Phase: NA • Sponsor: Academy Het Dorp • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New hope for prostate cancer recurrence: targeted radiation plus radioactive drug combo tested
Disease control OngoingThis phase I trial tests the safety, side effects and best dose of radioligand therapy (lutetium Lu 177 PSMA-10.1 \[177Lu-rhPSMA-10.1\]) after prostate specific membrane antigen (PSMA) positron emission tomography (PET)-guided external beam radiotherapy in treating post-prostatec…
Phase: PHASE1 • Sponsor: Emory University • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Blood test could sniff out fatal fungus before It's too late
Diagnosis Recruiting nowMucormycosis (MM) is one of the main invasive fungal infection (IFI), and is determined by filamentous fungi belonging to the order of Mucorales, with a mortality rate ranging from 20 to 60% according to localization. Prompt initiation of adequate antifungal therapy is critical f…
Sponsor: University Hospital, Lille • Aim: Diagnosis
Last updated Jun 27, 2026 12:37 UTC
-
New antibody shot shows promise for HIV control and prevention
Disease control OngoingThis is an open-label phase 1b clinical trial enrolling people living with HIV (PLWH) who are antiretroviral therapy (ART)-naïve or have not been on ART for \> 24 weeks. This study will enroll PLWH to assess the safety, tolerability, and antiviral effect of bispecific and long-ac…
Phase: PHASE1 • Sponsor: David Ho • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Brain-Protecting diet and exercise trial launches for black adults with high blood pressure
Prevention Recruiting nowThe goal of this randomized controlled trial is to determine the impact of Mediterranean-Dash Intervention for Neurodegenerative Delay (MIND) diet and aerobic training on cognition in Black adults with high systolic blood pressure. Researchers will compare Food Delivery and Cook…
Phase: NA • Sponsor: Indiana University • Aim: Prevention
Last updated Jul 24, 2026 00:00 UTC